{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:25Z","timestamp":1786987045001,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:21:46Z","timestamp":1728087706000},"page":"1059-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug Review and Approval Policies Based on Real-world Evidence in China and the United States: A Comparative Study"],"prefix":"10.1016","volume":"46","author":[{"given":"Munire","family":"Mohetaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adili","family":"Tuersun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.009_bib0001","unstructured":"Belson N. FDA's historical use of \u201creal world evidence\u201d. 2018. https:\/\/www.fdli.org\/2018\/08\/update-fdas-historical-use-of-real-world-evidence (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0002","unstructured":"FDA. Real-world evidence. 2023. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0003","first-page":"1","article-title":"Establishment of RWS guidance reflecting contributions of China to regulatory science","volume":"17","author":"Wang","year":"2024","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0004","unstructured":"U.S. Food and Drug Administration. 21st Century Cures Act. 2016. https:\/\/www.congress.gov\/114\/plaws\/publ255\/PLAW-114publ255.pdf (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0005","unstructured":"U.S. Food and Drug Administration. Framework for FDA's real-world evidence program. 2018. https:\/\/www.fda.gov\/media\/120060\/download (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0006","unstructured":"National Medical Products Administration (China). Guideline on using real-world evidence to support drug research & development and evaluation (Trial). 2020. https:\/\/www.Nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20200107151901190.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0007","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Guideline on using real-world study to support research & development and evaluation of pediatric drugs (Trial). 2020. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20200901104448101.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0008","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Technical guideline for real-world data to generate real-world evidence (Trial). 2021. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/2a1c437ed54e7b838a7e86f4ac21c539 (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0009","unstructured":"U.S. Food and Drug Administration. Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. 2021. https:\/\/www.Fda.gov\/media\/152503\/download (accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0010","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation.Technical Guideline for Communication under Registration Review Evidence System Based on \u201cThree Combinations\u201d(Trial). 2022. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/8a1682a8d37494732f7f441dd11f5af6 (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0011","unstructured":"Hainan Provincial Drug and Medical Device Evaluation Service Center(China). Information Requirements for Declarations of Imported Drugs of Clinical Imperative in Boao Lecheng Pilot Zone of Hainan for the First Audit of Real World Study (Trial). 2022. https:\/\/amr.hainan.gov.cn\/himpa\/HICDME\/zxdt\/202206\/P020220616368022976798.pdf (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0012","unstructured":"U.S. Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products. 2022. https:\/\/www.fda.gov\/media\/124795\/download (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0013","unstructured":"U.S. Food and Drug Administration. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/164960\/download (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0014","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation.Guideline for real-world study design and protocol framework for drugs (Trial). 2023. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/14aac16a4fc5b5841bc2529988a611cc (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0015","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation.Technical guideline for communication of real-world evidence support to drug registration applications (Trial). 2023. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/8b59a85b13019b5084675edc912004f1 (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0016","unstructured":"U.S. Food and Drug Administration. Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products. 2023. https:\/\/www.fda.gov\/media\/164960\/download (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0017","series-title":"Applicable Technical Guidance for the Design of Single-Arm Clinical Trials to Support the Marketing Authorization Application of Anticancer Drugs","year":"2023"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0018","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation.Guiding Principles for the Application of Real-World Disease Registry-Based Data (Draft). 2023. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/01181ec42968738d304ff02511a21293 (accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0019","unstructured":"U.S. Food and Drug Administration. Data Standards for Drug and Biological Product Submissions Containing Real-World Data Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/153341\/download (accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0020","unstructured":"U.S. Food and Drug Administration. Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. 2023. https:\/\/www.fda.gov\/media\/154449\/download (accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0021","article-title":"Real-world evidence for regulatory decision-making: updated guidance from around the world","volume":"10","author":"Burns","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0022","unstructured":"National Medical Products Administration (China). Special provisions for the registration and management of Chinese medicines. 2023. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/xzhgfxwj\/20230210173401120.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0023","unstructured":"State Council Office of the People's Republic of China. Implementing Opinions on Comprehensively Strengthening Capacity Building for Drug Regulation. 2021. http:\/\/www.Gov.cn\/zhengce\/content\/2021-02\/09\/content_5586278.htm (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0024","unstructured":"State Council Office of the People's Republic of China. Circular on Certain Policy Measures to Accelerate the Development of Chinese Medicine Specialties. 2021 http:\/\/www.gov.cn\/zhengce\/content\/2021-02\/09\/content5586278.htm (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0025","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Clinical Research and Development of New Drugs for Traditional Chinese Medicine Compound Preparations Based on Experience (Trial). 2022. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/8a1682a8d37494732f7f441dd11f5af6 (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0026","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Technical Guideline for Communication under Registration and Review Evidence System Based on \u201cThree Combinations\u201d (Trial). 2022. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/8a1682a8d37494732f7f441dd11f5af6(Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0027","unstructured":"National Medical Products Administration (China). National Plan for Drug Safety and the Promotion of Quality Development in the Fourteenth Five-Year Plan. 2021. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjzh\/20211230192314164.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0028","unstructured":"People's Government of Hainan Province (China). Regulations of Boao Licheng International Medical Tourism Advance Zone of Hainan Free Trade Port. 2020. https:\/\/www.hainan.gov.cn\/hainan\/dfxfg\/202006\/a71c9003a5694eed84d70e138bc4160c.shtml (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0029","unstructured":"Hainan Free Trade Port Investment and Talent Attraction Network. Bo'ao Lecheng International Medical Tourism Priority Area. https:\/\/www.contacthainan.gov.cn\/xinwen\/show-5084.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0030","unstructured":"Hainan Provincial Drug Administration (China). Notice on the Release of Service Guidelines for Pilot Real-World Study on Drugs in Boao Lesheng International Medical Tourism Pioneering Zone, Hainan. 2021. https:\/\/hnrws.cn\/uploads\/file\/20220316\/09\/c4f708eb0b700278ca42fa7f0fb6e3e6.pdf (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0031","unstructured":"Hainan Provincial Drug Administration (China). Declaration Guidelines for Imported Medicines and Medical Devices for Clinical Emergencies in Boao Licheng International Medical Tourism Advance Zone of Hainan Free Trade Port. 2021. https:\/\/amr.hainan.gov.cn\/himpa\/xxgk\/tzgg\/202110\/t20211015_3075673.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0032","unstructured":"U.S. Food and Drug Administration. Study Data Technical Conformance Guide. 2021. https:\/\/www.fda.gov\/industry\/fda-resources-data-standards\/study-data-standards-resources (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0033","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Real-world data research continues to heat up, with 10 medicines included in the first pilot. 2022. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/e3cd052e638876697399de962b7354a4 (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0034","article-title":"Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0035","unstructured":"U.S. Food and Drug Administration. FDA Discusses RWD, RWE With Industry, Academia. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/7\/fda-discusses-rwd-rwe-with-industry-academia (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0036","unstructured":"Hainan Province Real World Data Research Institute (China). First-line experts share their practical experience in real research at home and abroad, and this training in LeCheng attracted nearly 1,000 participants. 2022. https:\/\/hnrws.cn\/event\/1422\/2453.html (Accessed July 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0037","unstructured":"National Medical Products Administration (China) Center for Drug Evaluation. Management measures for communication and exchange of drug development and technical review. 2020. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/b823ed10d547b1427a6906c6739fdf89 (Accessed July 2023)."},{"issue":"5","key":"10.1016\/j.clinthera.2024.09.009_bib0038","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinthera.2020.03.006","article-title":"Use of real-world data for new drug applications and line extensions","volume":"42","author":"Bolislis","year":"2020","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.009_bib0039","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clinthera.2021.12.010","article-title":"Real-world data in the postapproval setting as applied by the EMA and the US FDA","volume":"44","author":"Mofid","year":"2022","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.009_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The role of real-world evidence in FDA-approved new drug and biologics license applications","volume":"111","author":"Purpura","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0041","unstructured":"The International Society for Pharmacoeconomics and Outcomes Research. Examine the use of real-world evidence to support FDA decision-making for new drug applications and biologics license applications from 2021 to 2022. 2023. https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/intl2024-3900\/135826 (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0042","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1759-7714.12650","article-title":"Real world study of regimen containing bevacizumab as frst-line therapy in Chinese patients with advanced non-small cell lung cancer","volume":"9","author":"Xing","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0043","unstructured":"National Medical Products Administration (China). Conditional approval for platinib capsules launched. 2021. https:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/20210324140443175.html (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0044","unstructured":"National Medical Products Administration (China). 2022 Drug Approval Document Pending Receipt Information Release. 2022. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20220620141308104.html (accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0045","unstructured":"National Medical Products Administration (China). 2022 Drug Approval Document Pending Receipt Information Release. 2022. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20220713085333108.html (accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0046","unstructured":"National Medical Products Administration (China). August 24, 2023 Drug Approval Document Delivery Information Release. 2023. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20230824155809182.html (accessed December 2023)."},{"issue":"6","key":"10.1016\/j.clinthera.2024.09.009_bib0047","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s43441-023-00555-9","article-title":"Use of real-world evidence for drug regulatory decisions in china: current status and future directions","volume":"57","author":"Li","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clinthera.2024.09.009_bib0048","unstructured":"Guangdong Provincial Drug Administration(China). \u201cPneumonia No. 1 Formula\u201d was approved to be used in 30 designated hospitals in Guangdong for the treatment of new coronary pneumonia. 2020. https:\/\/mpa.gd.gov.cn\/xwdt\/xwfbpt\/mtzx\/content\/post_2890790.html (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0049","unstructured":"Zhejiang Provincial Drug Administration (China). Real world research on traditional Chinese medicine in Wenzhou municipality achieves first results in the province. 2022. http:\/\/mpa.zj.gov.cn\/art\/2022\/9\/9\/art_1228989352_58929869.html (Accessed December 2023)."},{"key":"10.1016\/j.clinthera.2024.09.009_bib0050","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. International harmonisation of real-world evidence terminology and convergenceof general principles regarding planning and reporting of studies using real-WorloData, with a focus on effectiveness of medicines. 2023. https:\/\/ich.org\/page\/reflection-papers (Accessed December 2023)."},{"issue":"3","key":"10.1016\/j.clinthera.2024.09.009_bib0051","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clinthera.2022.01.012","article-title":"Real-world evidence for regulatory decision-making: guidance from around the world","volume":"44","author":"Burns","year":"2022","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T15:00:38Z","timestamp":1733842838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002716"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Review and Approval Policies Based on Real-world Evidence in China and the United States: A Comparative Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}